The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and substantial returns is undeniable, the associated risks are also significant. Many o